Wall Street brokerages expect BioTelemetry Inc (NASDAQ:BEAT) to post earnings per share of $0.43 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for BioTelemetry’s earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.41. BioTelemetry reported earnings of $0.39 per share in the same quarter last year, which would indicate a positive year over year growth rate of 10.3%. The firm is expected to report its next quarterly earnings report on Wednesday, April 24th.
According to Zacks, analysts expect that BioTelemetry will report full year earnings of $1.94 per share for the current financial year, with EPS estimates ranging from $1.80 to $2.18. For the next financial year, analysts anticipate that the company will post earnings of $2.19 per share, with EPS estimates ranging from $2.09 to $2.36. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.43 by $0.13. The firm had revenue of $103.60 million during the quarter, compared to analysts’ expectations of $102.84 million. BioTelemetry had a return on equity of 24.46% and a net margin of 10.72%. BioTelemetry’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the business earned $0.32 earnings per share.
Several research analysts recently commented on the company. Benchmark set a $82.00 target price on BioTelemetry and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. ValuEngine cut BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $84.00 target price for the company in a research report on Thursday, February 28th. Lake Street Capital set a $90.00 target price on BioTelemetry and gave the stock a “buy” rating in a research report on Friday, February 22nd. Finally, Sidoti set a $95.00 target price on BioTelemetry and gave the stock a “buy” rating in a research report on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $80.33.
In other BioTelemetry news, CFO Heather C. Getz sold 64,989 shares of BioTelemetry stock in a transaction on Friday, January 25th. The stock was sold at an average price of $70.09, for a total transaction of $4,555,079.01. Following the completion of the transaction, the chief financial officer now directly owns 119,085 shares of the company’s stock, valued at $8,346,667.65. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Heather C. Getz sold 93,383 shares of BioTelemetry stock in a transaction on Tuesday, January 29th. The shares were sold at an average price of $70.06, for a total value of $6,542,412.98. Following the transaction, the vice president now directly owns 119,085 shares of the company’s stock, valued at $8,343,095.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 177,198 shares of company stock valued at $12,419,736. Company insiders own 6.50% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of BEAT. BlackRock Inc. lifted its holdings in shares of BioTelemetry by 7.8% during the third quarter. BlackRock Inc. now owns 4,957,817 shares of the medical research company’s stock valued at $319,531,000 after acquiring an additional 360,529 shares during the period. Deutsche Bank AG increased its stake in shares of BioTelemetry by 119.7% in the fourth quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock valued at $18,556,000 after buying an additional 169,306 shares in the last quarter. Legal & General Group Plc increased its stake in shares of BioTelemetry by 213.4% in the fourth quarter. Legal & General Group Plc now owns 219,499 shares of the medical research company’s stock valued at $13,054,000 after buying an additional 149,453 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of BioTelemetry by 332.4% in the third quarter. Point72 Asset Management L.P. now owns 92,100 shares of the medical research company’s stock valued at $5,936,000 after buying an additional 70,800 shares in the last quarter. Finally, Vanguard Group Inc increased its stake in shares of BioTelemetry by 2.8% in the third quarter. Vanguard Group Inc now owns 1,900,117 shares of the medical research company’s stock valued at $122,462,000 after buying an additional 52,363 shares in the last quarter. 88.51% of the stock is owned by institutional investors.
BEAT stock traded down $2.06 during midday trading on Friday, hitting $56.06. The stock had a trading volume of 13,333 shares, compared to its average volume of 593,050. The stock has a market cap of $1.96 billion, a P/E ratio of 28.96 and a beta of 1.43. BioTelemetry has a 52 week low of $32.65 and a 52 week high of $80.92. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Story: Trading Ex-Dividend Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.